TRIA Bioscience

Tria Bioscience is a biotechnology company focused on the discovery and development of novel molecular glue degraders to target "undruggable" proteins. Launched in 2024 with significant Series A funding, the company utilizes a proprietary platform that integrates structural biology, computational chemistry, and high-throughput screening to identify small molecules that facilitate protein-protein interactions. Tria's initial therapeutic focus is on oncology and immunology, aiming to expand the reach of targeted protein degradation beyond current limitations. The company's approach seeks to harness the body's natural protein disposal system to eliminate disease-causing proteins that cannot be reached by traditional inhibitors. Headquartered in Cambridge, Massachusetts, Tria is led by an experienced management team and backed by a syndicate of top-tier life science investors.